Chronic kidney disease is common and patients with many co-morbid conditions frequently have to undergo surgical procedures and, therefore, require effective pain management. The pharmacokinetics of various analgesic agents are not well studied in patients with chronic kidney disease and the risk of accumulation of the main drug or their metabolites, resulting in serious adverse events, is a common scenario on medical and surgical wards. It is common for these patients to be cared for by 'non-nephrologists' who often prescribe the standard dose of the commonly used analgesics, without taking into consideration the patient's kidney function. It is important to recognize the problems and complications associated with the use of standard doses of analgesics, and highlight the importance of adjusting analgesic dosage based on kidney function to avoid complications while still providing adequate pain relief. 
Chronic kidney disease (CKD) is common 1 and is regularly accompanied with various co-morbidities. Often these patients with various co-morbidities undergo operative procedures and require analgesics. The most-responsible physician providing the care to these individuals during their hospitalization is often a non-nephrologist. Opioids are commonly used in the management of post-operative pain, and often a standard dose is used by the health-care providers without taking into consideration kidney function 2 . In North America, morphine and meperidine (Demerol) still remain the commonly used parenteral agents, and acetaminophen with codeine (Tylenol #3) a commonly used oral agent for management of post-operative pain in patients with 3 and without renal failure. Prolonged central nervous system and ventilatory depression due to morphine and other opioids have been known for over a century in patients with kidney failure 4-10 and the various contributing factors are outlined in Table 1 . Despite the increased potential for respiratory depression, especially in patients with CKD, life-threatening cases of opiate toxicity continue to occur not only in patients with kidney disease 11 , but also in patients without kidney disease 12, 13 . It is important to highlight the issue of central nervous system (CNS) and respiratory depression with opioid analgesics in patients with CKD and formulate strategies to prevent these complications, while providing effective pain relief.
In addition to the post-operative pain, patients with CKD may have underlying chronic pain that is often multi-factorial 14 i.e., ischemic pain from peripheral vascular disease, neuropathic pain of polyneuropathy (diabetes), bone pain from osteoporosis or dialysis-associated amyloidosis, and musculoskeletal pain that may or may not be related to kidney disease. Post-operative pain is often nociceptive, whereas chronic pain may be nociceptive, neuropathic or mixed. It is also important to recognize that depression is common in CKD 15 and that it may complicate the management and patient's ability to cope with pain 16 .
Assessment of pain
Assessment of pain requires detailed history to elucidate the cause of pain, its location, nature (acute, chronic or acute and chronic), intensity and its impact on physical, social and emotional functioning 17 .
Spectrum of pain
Acute pain is a protective and an adaptive response to injury, whereas chronic pain or the persistence of pain beyond the healing phase is a maladaptive 18 . Acute pain results from direct stimulation of sensory neurons, called nociceptors. Nociceptors have two types of axons, the rapidly conducting thinly myelinated Aδ fibers that mediate the initial phase of acute pain that is extremely sharp pain, and the more slowly conducting unmyelinated C fibers mediate the second phase of acute pain that is more prolonged and less intense following injury. Nociceptors can be stimulated by mechanical, thermal, chemical and inflammatory stimuli 18 .
Pain lasting longer than 3 months or beyond the duration required for complete tissue healing is called chronic pain. It may be nociceptive, resulting from prolonged tissue injury with persistent activation of nociceptors, neuropathic resulting from a lesion or a process affecting the somatosensory system or mixed processes.
Changes from Version 2
We have taken Dr Carns' second referee report into consideration and have made changes to the manuscript where appropriate.
See referee reports
Changes from Version 1
Addressing concerns regarding the reduced use of meperidine, we understand that meperidine is not commonly used in Europe and possibly United States, but it is still used in some countries.
As the readership of the journal is not limited to North America or Europe, we felt, as also suggested, that the issues with renal insufficiency are substantial and for this reason we included this in the clinical scenario.
As suggested, we have now included a statement in the discussion regarding 'adjuvant medications' that dose reduction may be required for patients with renal insuffciency.
We have made corrections to the manuscript regarding the dosing recommendations in the acetaminophen section. We would like to be clear that the recommendation to give half of the daily dose followed by 'round the clock' dosing is opinion based, and an effort to avoid overdosing and possible toxicity. The author (MSP) finds this method useful for controlling symptoms whilst, at the same time, preventing toxicity.
We have also addressed the more minor concerns with our manuscript such as replacing the word 'narcotic' with the word 'opioid' where appropriate, made modifications to Table 2 , including a subnote to explain this, and we have included the various metabolites of codeine. We have also decided to leave propoxyphene in the discussion, as this may still be used in certain parts of the world, and since F1000Research is an international journal, this may be valuable to a number of readers.
demand" basis rather than "by the clock"
17
. We suggest consider prescribing at least half of total daily dose "by the clock" (opinion MSP) e.g., Acetaminophen 500 mg four times a day and remaining dose could be given "on demand" or in combination with other agents.
Intensity of pain
Pain intensity may be measured by one of the major pain rating scales including verbal, numerical and visual analogue scales. However, a numerical rating scale comprising of a range of numbers from 0 to 10, is the most widely used system in clinical practice and is generally based on a subjective 10-point scoring system, where 0 denotes the absence of pain and 10 the worst pain imaginable 19 .
Pain management
Effective pain management requires a multifaceted approach with an understanding of the type (nociceptive, neuropathic or mixed), underlying cause, assessment of intensity and duration of pain 17 . In addition, assessment of concomitant medications and co-morbidities is important when selecting analgesic agent(s). Adjuvant analgesics and non-pharmacological methods of pain control are important to consider in such circumstances 17 . We review the strategies to manage acute pain in CKD with main focus on the use of opioids since most of the challenges occur in the use of opioids in CKD.
In 2005, a modified World Health Organization (WHO) step-wise approach was proposed for pain management in patients with CKD 20 ( Figure 1 ) and this approach was found to be effective in acute pain control in >90% of hemodialysis patients, at least short-term, in a 4-week study 21 . This approach is important to follow to achieve 'balanced analgesia' by effectively utilizing 'co-analgesics' (Box 1).
Non-opioid analgesics
Acetaminophen: Has potent analgesic and antipyretic properties and is effective in various acute and chronic painful syndromes. It is the analgesic of choice in the elderly and in patients with kidney disease 22 and should be considered in all patients (except in patients with hepatic insufficiency) experiencing pain, regardless of pain level, until pain is relieved or up to a maximum dose of 3,000 mg a day 23 or 2.6 g/d in high-risk patients 24 (malnourished or alcoholic). It often does not require dose adjustment in CKD but some authors recommend increasing dosing interval from every six to eight hours when GFR is <10 mL per minute 25 . Acetaminophen is underutilized in the peri-operative period and when prescribed it is often in an "on 28 . § Routes that use first pass metabolism results in higher production of metabolites than those that bypass it. ¶ P-glycoprotein inhibitors increase uptake of M6G across blood brain barrier 16, 17 . º Concomitant antibiotics by altering bacterial flora reduces bacterial glucuronidase, resulting in reabsorption of M6G. @ Extensive 2D6 metabolism may occur in up to 1/3 rd of patients of east African heritage -increasing the risk of opioid overdose from codeine.
Step 1
Mild pain

Score 1-3
Non-opioid ± Adjuvant Acetaminophen Non-steroidal anti-inflammatory drugs (NSAIDs), Cyclo-oxygenase-2 (Cox-2) inhibitors [only for short-term]* Carbamazepine Gabapentin Pregablin Tricyclic antidepressants
Step 2
Step 3
Moderate pain
Score 4-6
Severe pain
Score 7-10
Non-opioid ± Adjuvant ± Weak opioid
Oxycodone with acetaminophen ± Oxycodone (2) Hydromorphine (3.5-7.5) Fentanyl/alfentanil (50-100) Methadone (10) Buprenorphine Anti-inflammatory agents: Nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase (COX-2) inhibitors block prostaglandin synthesis and, when used as co-analgesic, reduce opioid need by 30-50%. However, because of their gastro-intestinal and cardio-renal side effects, they should be avoided for prolonged use in CKD, as these agents may decrease renal blood flow and may precipitate acute renal failure and can cause life-threatening hyperkalemia. However, if used, it should be for short term management (3 to 7 days) of acute pain and consider short-acting agents 26 with careful monitoring of renal function and serum potassium.
Adjuvant analgesics
Adjuvant analgesics are medications with a primary indication other than pain that may possess analgesic activity or modify pain response. These are often helpful for management of chronic neuropathic pain. Examples include cabamezapine, gabapentin, and pregabalin. These agents are not required for management of acute pain. However, CKD patients may have associated underlying chronic neuropathic pain that could affect acute pain response or management. Therefore, some patients may already be taking these agents for control of their 'chronic pain' and these agents may be stopped inadvertently in the peri-operative period. If this is the case, adjuvant analgesics should be resumed when possible, with considerations being taken for the possible drug-drug interactions when prescribing opioid analgesics for acute pain. It is important to understand that the dose of these agents (adjuvants) may also need to be reduced because of renal dysfunction.
Opioids
The relative potency of commonly used opioids is shown in Table 2 . As most opioids or their metabolites are excreted by the kidneys, dosage adjustment is often required when estimated glomerular filtration rate (eGFR) falls below 50 ml/min or during stages 3b, 4 and 5 of CKD, and for patients on dialysis (Table 2) 27,28
. In addition to CNS and respiratory depression, constipation is a common side effect that is important to identify and manage, especially in patients on peritoneal dialysis, as constipation is the common cause of catheter malfunction 29 , and appropriate laxatives should be used in conjunction with treatment.
Morphine: Morphine is the most studied opiate in kidney disease. It is primarily an agonist at the µ-receptors with pain relief at µ 1 -receptors, and causes respiratory depression and constipation through its agonist action at µ 2 -receptors 14 . Morphine is metabolized in the liver to several metabolites 30 . Of these diamorphine and morphine-3-glucuronide (M3G) do not bind to opiate receptors, whereas normorphine and morphine-6-glucuronide (M6G) do, with M6G being approximately 10-fold more potent than morphine 31 . All metabolites are excreted in the urine along with about 10% of the parent compound. M6G accumulates in kidney failure and causes CNS and respiratory depression 32 . M6G crosses the blood brain barrier (BBB) slowly, and once it crosses the BBB, the CNS effects may be prolonged and may persist after stopping morphine or after hemodialysis, as the M6G slowly re-equilibrates across the BBB back into systemic circulation 6 . Transport of M6G across the BBB is an active process mediated by 170-kd P-glycoprotein. P-glycoprotein is an ATP-dependent carrier system that acts as an efflux pump to transport chemicals or metabolites from endothelial cells to vascular compartment and inhibition of this results in an increase of M6G in the brain 33, 34 . The analgesic and respiratory depressant effects are related to serum concentrations of both morphine and M6G 31 . A dosage reduction of 25%, 50% and 75% is recommended in patients with mild (stage 3), moderate (stage 4) and severe kidney failure (stage 5) respectively. However, 20-25% of patients may tolerate the full dose of morphine without ill-effects because of A118G polymorphism 35, 36 .
Meperidine: Normeperidine, an active metabolite of meperidine, is neurotoxic and accumulates in renal failure and may cause a range of neuroexcitatory effects ranging from irritability to agitation to seizures 37 . Although normeperidine is removed by hemodialysis 38 , its regular administration is contraindicated in patients with any degree of renal failure 39 .
(Dextro)Propoxyphene: It is no longer available in North America and its metabolite norpropoxyphene is excreted by the kidneys and accumulates in renal failure 39 . This results in CNS and respiratory depression, cardiac conduction disturbances and hypoglycemia. Both the parent drug and its metabolite are not removed by hemodialysis and is contraindicated in patients with renal failure 39 .
Hydromorphone:
Hydromorphone is an analogue of morphine with shorter duration of action and with excellent efficacy in moderate to severe pain. It is five to seven times potent than morphine. It is eliminated by both hepatic (60%) and renal routes 40 . Hydromorphone doesn't accumulate in renal failure because of its rapid conversion to its less-potent metabolite hydromorphone-3-glucuronide (H3G) that accumulates in renal failure but is effectively removed by hemodialysis 41 . However, typical opioid adverse effects have been reported in patients with renal failure 42 , but experience suggests efficacy without excess toxicity, if monitored carefully 43 . Codeine/Dihydrocodeine: Codeine is metabolized by the liver to a variety of active metabolites (codeine-6-glucuronide, norcodeine, morphine, M3G, M6G, and normorphine) that are renally excreted 44 . The half-life of codeine is prolonged 5-fold in hemodialysis patients 45 . Codeine and its metabolites accumulate in renal failure and can cause hypotension and CNS and respiratory depression 46, 47 . A similar elimination pathway is proposed for elimination of dihydrocodeine, although this has not been fully evaluated 39 . Dihydrocodeine can cause prolonged narcosis after therapeutic doses in patients with acute 48 or chronic renal failure 49 . Therefore, these agents should be used with caution in patients with renal failure.
Box 1. Glossary.
Opiate: Naturally occurring alkaloid i.e., morphine or codeine.
Opioid: Any natural or synthetic compound that has morphine-like properties.
Balanced analgesia: Principle of combining different classes of analgesics to optimize efficacy while minimizing side-effects.
Co-analgesic: A drug administered alongside opioids enabling a reduction in opioid dose.
Adjuvant: A substance that helps and enhances the pharmacologic effects of an agent (analgesic). 39 . Fentanyl is highly protein bound (80-86%), has a high volume of distribution, and removal by hemodialysis is negligible 58, 59 . Opioid-naïve patients should not be initiated on transdermal fentanyl because of its variable absorption.
Tramadol:
Tramadol is an opioid analgesic that also inhibits serotonin and noradrenaline reuptake. It is extensively metabolized by the liver and 30% of the parent drug and 60% of active metabolites are excreted in the urine 60 . It is effective for both nociceptive and neuropathic pain and has the advantage of less sedation and respiratory depression compared to other opiates. A common side effect is nausea. A rare but important side effect is seizures, especially in patients taking medications that lower the seizure threshold, like selective serotonin reuptake inhibitors (SSRI). In addition, tramadol may precipitate serotonin syndrome 61 (a potentially life-threatening drug-interaction manifested by excess serotonin effect resulting in cognitive, autonomic and somatic effects) in patients taking SSRI 62 . In advanced CKD, the elimination half-life of tramadol may double 60 and the dose should be decreased to 100 mg every 12 hr in patients with eGFR of 30 ml/min and 50 mg every 12 hr when eGFR is <10 ml/min. Tramadol is significantly removed by dialysis and should be administered after hemodialysis on dialysis days 63 .
Methadone: Methadone is a synthetic opioid with five to 10 times the potency of morphine, is highly protein bound (70-87%) and has a half-life of 30 hr. Approximately 20% after a single dose is excreted unchanged and about 30% as inactive metabolites in the A reduction in dose by 50% is suggested for codeine in renal failure 39, 45 and chronic use should be avoided.
Oxycodone: Oxycodone is a strong opioid with a higher oral bioavailability. It is metabolized by the liver to active metabolitesnoroxycodone and oxymorphone
50
. Approximately 19% of the drug is excreted unchanged in the urine. The clearance of oxycodone and its metabolites is reduced in renal failure 50 and results in an increase in plasma concentration by 50% and prolongation of its half-life by an hour 50 . There is lack of consensus of its use in CKD because of varied case reports of toxicity and good tolerance. When required, use cautiously and start with a lower dose 51 .
Buprenorphine: Buprenorphine is a long-acting semi-synthetic partial agonist with the advantage of having less respiratory depression and hypotension 52,53 but has a ceiling effect 54, 55 . There is no significant difference in the clearance of the drug in patients with normal or impaired renal function. It has limited oral bioavailability because of an extensive first-pass metabolism. Sublingual, transdermal or parenteral administration is required. It is extensively metabolized by the liver with less than 30% renal excretion. The metabolite norbuprenorphine may accumulate in renal failure that has minor analgesic activity. Buprenorphine is 96% protein bound so is not dialyzable 56 .
Fentanyl, Alfentanil, and Sufentanil: Fentanyl, Alfentanil and Sufentanil are potent opioid receptor agonists, with a rapid onset of action and shorter duration of action. Fentanyl is rapidly metabolized in liver to inactive metabolites. Less than 10% of the parent drug is excreted in urine with no significant accumulation in CKD, but there is considerable inter-patient variability in fentanyl pharmacokinetics when given as a continuous infusion or via transdermal route. However, no dosage modification is necessary in patients with renal failure when fentanyl is given as a bolus. However, Table 3 . Pain management in CKD.
Pain intensity WHO analgesic step Agent(s) of choice Comments
Mild pain Score 1-3
Non-opioid ± Adjuvant Acetaminophen 500 mg q6h (by the clock) and 325 mg every 6-8h as required • Before prescribing analgesics, consider kidney function to avoid toxicity that may occur from accumulation of the parent drug or their metabolites.
• The general principles of pain assessment and management should be adopted and analgesia should be prescribed incorporating the modified WHO analgesic ladder.
• Co-analgesics like acetaminophen should be considered "by the clock" rather than "by demand".
• Do not write standing (or long-term) orders for opioids.
Reassess the need and the dose of opioids every 24-48 hr.
• Avoid fentanyl transdermal patch in opioid-naïve patients.
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The author(s) declared that no grants were involved in supporting this work. urine 39 . There is a 3-fold increase in the excretion of metabolites on chronic dosing, suggesting enhanced metabolism 64 . The removal by hemodialysis is insignificant 65 . Although in 2 patients with CKD the plasma concentrations were no higher than patients with normal renal function 66 , there is a well-described risk of accumulation and toxicity with methadone, even in patients with normal renal function, so experienced specialist supervision is warranted. A dose reduction of 50% to 75% is suggested in patients with renal failure, but it is difficult to use in patients with CKD because of its long half-life and wide inter-individual variation in clearance 65 . In some countries, methadone may require a specialist in pain management with a special license to prescribe it, and that may limit its use in acute pain management. However, methadone should not be used in opioid naïve patients.
Summary
Patients with CKD have a high burden of co-morbidities that modulate pain response, and when these individuals undergo operative procedures, standard orders for pain control can be written without taking into consideration the patient's kidney function. Unfortunately, the data on the effects and tolerability of various analgesic agents are limited in such individuals and, given the lack of data, the recommendations are mainly based on expert opinion 17, 67 in patients with CKD with 68 and without dialysis 43 . The general principles of pain assessment and management should be adopted and analgesia should be prescribed incorporating the modified WHO analgesic ladder 20 in patients with CKD, with close and frequent monitoring for side effects of drug or its metabolite accumulation. The nephrologist and a pharmacist should be involved in the management of these patients. The non-opioid analgesics should be used early and 'by the clock', rather than 'on-demand', and the need for opioid analgesics should be re-evaluated every 24-48 hr, as most patients may tolerate the prescribed initial dose of the opioid analgesics,
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No competing interests were disclosed. The first clinical scenario includes meperidine as a drug used in the patient. The use of meperidine has significantly been reduced in the USA and is monitored as a negative finding when used in patients over 60. Thus hospitals have made efforts to reduce or eliminate its use except in treatment of rigors and given in low doses only. I am not sure if this would be the best scenario to start the article, although its issues with renal insufficiency are substantial.
I would refrain from the use of the word 'narcotic' in your discussion in favor of the word opioid.
In the discussion regarding 'adjuvant medications' there is no mention that nearly all these medications require dose adjustments in renal insufficiency. Since the article focuses on this topic, I believe it should be included beyond just mentioning that some patients may be using these medications.
The last sentence in the 'Acetaminophen' section gives specific dosing recommendations to give half of the daily dose followed by round the clock dosing. Is this opinion or should a reference be included?
Since propoxyphene is no longer available, I would consider eliminating it from the discussion. I am unsure if it is still being used in other countries. If so, I guess I would leave it in.
The Codeine/Dihydrocodeine paragraph makes no mention of the active metabolite morphine from codeine. Discussion of other drugs in this section refer to actual names of metabolites. Given that morphine was discussed earlier in the document, including this information is important in my view.
The chart indicating % amounts in the column headed by eGFR/ml rates does not really say that the percentages indicate a percent dose reduction. It should be made more clear even though obvious to me. The methadone section says that it requires a special license to prescribe. This is not entirely true. The special license is only required when treating opioid addiction. If methadone is used for pain control, no special license is needed. I would also include that methadone is not to be used in opioid naïve patients as you do with the fentanyl patch.
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